Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937201 | 0.94 | RAB9A (0.55) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL3765919 | 0.83 | CA12 (0.59) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL25845706 | 0.82 | CA12 (0.59) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL7428266 | 0.82 | CA12 (0.54) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL7428282 | 0.82 | MAPT (0.60) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL24513853 | 0.81 | LNPEP (0.50) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL29145378 | 0.81 | LNPEP (0.50) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL474941 | 0.81 | HDAC1 (0.65) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL10522559 | 0.81 | CA12 (0.53) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL5317709 | 0.80 | PDK1 (0.75) | KMT2AMEN1ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | claimed |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| WO-2023011416-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | 中国海洋大学 | 2023-02-09 | — | — | WO | disclosed |
| EP-3320921-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190209572-A1 | BIFUNCTIONAL ANTIFUNGAL AGENTS AND METHODS OF TREATING FUNGAL INFECTION | MERCK SHARP & DOHME CORP. | 2019-07-11 | — | — | US | disclosed |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-1999051565-A9 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE INC (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999051565-A1 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5369123-A | Anticholesterol agents, treatment of atherosclerosis, antilipidemic agents and treatment of hyperlipoproteinaemia | E. R. SQUIBB & SONS, INC. (US) | 1994-11-29 | — | — | US | disclosed |
| US-4994569-A | Cholecystokinin antagonists | RHONE-POULENC SANTE (FR) | 1991-02-19 | — | — | US | disclosed |
| EP-0203047-B1 | FLUORESCENT LANTHANIDE CHELATES | Kankare, Jouko (FI) | 1990-08-22 | — | — | EP | disclosed |
| US-4920195-A | Fluorescent lanthanide chelates | KANKARE JOUKO (FI) | 1990-04-24 | — | — | US | disclosed |
| EP-0203047-A1 | Fluorescent lanthanide chelates | Kankare, Jouko (FI) | 1986-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209572-A1 | BIFUNCTIONAL ANTIFUNGAL AGENTS AND METHODS OF TREATING FUNGAL INFECTION | ERG28, PAICS, BAK1 | CA12 919/4885CA1 2522/4885CA2 2187/4885 |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | PPIA, S100A4, S100A6 | CA12 2788/4885CA1 3142/4885CA2 2665/4885 |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | CA12 484/4885CA1 1165/4885CA2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.